NCT01634373已完成1 期
An Open-Label, Randomised, 2-Period, 2-Treatment, 2-sequence, Crossover, Steady State Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets [Test Formulation; Torrent Pharmaceuticals Ltd., India] Versus Seroquel® 300 mg Tablet [Reference Formulation; AstraZeneca, USA] in Schizophrenic Patients.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
Objective:
Primary objective was to study Steady-state bioequivalence of Torrent's Quetiapine Fumarate Tablets 300 mg.
Study Design:
Randomized, Two-Way, Crossover, multiple Dose, and Open-Label
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 25 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sex: Male of female
- •Age: 25-65 years
- •Patients who are receiving a stable daily dose of quetiapine 300 mg every 12 hourly for atlist one month
- •Patient willing to adhere to the protocol requirements
排除标准
- •Clinically relevant abnormalities in the results of the laboratory screening evaluation.
- •Clinically significant abnormal ECG.
- •Significant orthostatic hypotension (i.e., a drop in systolic blood pressure of 30 mm Hg or more and/or a drop in diastolic blood pressure of 20 mm Hg or more on standing)
- •Concurrent use of antihypertensive medication or any medication that might pre-dispose to orthostatic hypotension.
- •History of allergic reactions to quetiapine or other chemically related psychotropic drugs.
- •Concurrent primary psychiatric or neurological diagnosis including organic mental disorder, severe tardive dyskinesia, or idiopathic Parkinson's disease.
- •Existence of any surgical or medical condition, which in the judgement of the Principal Investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug or likely to compromise the safety of patients.
- •Concurrent use of other drugs known to suppress bone marrow function.
- •HIV, HCV, HBsAg positive.
- •Expected changes in concomitant medications during the period of study.
- •A history of epilepsy or risk for seizures
- •positive urine drug of abuse test at enrollment.
- •A history of alcohol or drug dependence by Diagnostic and statistical manual of Mental disorders IV(DSM-IV) criteria during the 6 month period immediately prior to study entry.
- •A total white blood cell count below 4000/ml, or absolute neutrophil count below 2000/ml
- •Female patients with pregnancy or Breast feeding or intend to become pregnant during the study and not able to follow contraception methods.
- •History of multiple syncopal episodes.
- •Administration any study drugs in last 3 months prior to entry in the study.
- •History of significant blood loss due to any reason in the past 3 months.
- •Any pre-existing bleeding disorder.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted ConditionsBipolar I DisorderNCT01570959Roxane Laboratories56
已完成
不适用
Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fasted ConditionsTreatment for Bipolar I DisorderNCT01570907Roxane Laboratories42
已完成
不适用
Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fed ConditionsBipolar I DisorderNCT01570894Roxane Laboratories42
已完成
1 期
Quetiapine Fumarate Immediate Release (IR) Versus Extended Release (XR) Dose Escalation ComparisonHealthy VolunteersNCT00702676AstraZeneca63
已完成
4 期
Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar DisorderAcute Mania in Bipolar DisorderNCT00672490AstraZeneca376